Literature DB >> 2881513

Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells.

M Osame, M Matsumoto, K Usuku, S Izumo, N Ijichi, H Amitani, M Tara, A Igata.   

Abstract

Six adult patients had a chronic progressive myelopathy that possessed the following features: high antibody titers to human T-lymphotropic virus type I (HTLV-I) in serum and cerebrospinal fluid (CSF); predominantly upper motor neuron disorder, symmetrical, with mild sensory and bladder disturbances; and presence of adult T-cell leukemia-like cells in both peripheral blood and CSF. We refer to this entity as HTLV-I-associated myelopathy (HAM). Electrophoretic studies of immunoglobulin G in CSF using Western blot analysis characteristically demonstrated p24 and p32 bands. Rates of intra-blood-brain barrier synthesis were determined and found increased in the patients with HAM. Corticosteroid treatment produced clinical improvement in all of 4 patients. A retrospective survey of CSF samples was carried out in 287 patients with neurological disorders, and 6 additional patients with HAM were identified.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881513     DOI: 10.1002/ana.410210203

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  114 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

2.  Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient.

Authors:  Ryuji Kubota; Samantha S Soldan; Roland Martin; Steven Jacobson
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

3.  HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

Authors:  T Matsuzaki; M Nakagawa; M Nagai; K Usuku; I Higuchi; K Arimura; H Kubota; S Izumo; S Akiba; M Osame
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

4.  Transgenic thymocytes are refractory to transformation by the human T-cell leukemia virus type I tax gene.

Authors:  M I Nerenberg; T Minor; J Price; D N Ernst; T Shinohara; H Schwarz
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

5.  Retinal vasculitis in human T-lymphotropic virus type I associated myelopathy.

Authors:  K Sasaki; I Morooka; H Inomata; N Kashio; T Akamine; M Osame
Journal:  Br J Ophthalmol       Date:  1989-10       Impact factor: 4.638

6.  Spontaneous cell proliferation is associated with poor sensitivity to glucocorticoids in patients infected with HTLV.

Authors:  R P Lopes; M Menna-Barreto; M E Bauer
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

7.  Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV-I-associated myelopathy/tropical spastic paraparesis patients.

Authors:  K Furukawa; M Mori; N Ohta; H Ikeda; H Shida; K Furukawa; H Shiku
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300.

Authors:  R Harrod; Y Tang; C Nicot; H S Lu; A Vassilev; Y Nakatani; C Z Giam
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Increased number of circulating HTLV-1 infected cells in peripheral blood mononuclear cells of HTLV-1 uveitis patients: a quantitative polymerase chain reaction study.

Authors:  A Ono; M Mochizuki; K Yamaguchi; N Miyata; T Watanabe
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

10.  T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones.

Authors:  K W Wucherpfennig; P Höllsberg; J H Richardson; D Benjamin; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.